Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000647111 | SCV000768898 | uncertain significance | Congenital muscular dystrophy due to integrin alpha-7 deficiency | 2022-09-19 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 224 of the ITGA7 protein (p.Gly224Ala). This variant is present in population databases (rs537950420, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ITGA7-related conditions. ClinVar contains an entry for this variant (Variation ID: 537988). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001592802 | SCV001823135 | uncertain significance | not provided | 2024-07-05 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Revvity Omics, |
RCV000647111 | SCV003811399 | uncertain significance | Congenital muscular dystrophy due to integrin alpha-7 deficiency | 2023-11-09 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001592802 | SCV004226347 | uncertain significance | not provided | 2023-06-09 | criteria provided, single submitter | clinical testing | PP3 |
Ambry Genetics | RCV004025723 | SCV004888258 | uncertain significance | not specified | 2024-01-12 | criteria provided, single submitter | clinical testing | The c.671G>C (p.G224A) alteration is located in exon 5 (coding exon 5) of the ITGA7 gene. This alteration results from a G to C substitution at nucleotide position 671, causing the glycine (G) at amino acid position 224 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV001592802 | SCV005191845 | uncertain significance | not provided | criteria provided, single submitter | not provided |